Cell-mediated response;GMFR of Anti-SAS-CoV-2 RBD IgG from baseline measured with ELISA;GMFR of Neutralizing anti-SARS-CoV-2 measured with live virus neutralization assay;GMT of Anti-SAS-CoV-2 RBD IgG measured with ELISA;GMT of Neutralizing anti-SARS-CoV-2 measured with live virus neutralization assay;Occurrence rate of Immediate Adverse Reaction (IAR);Occurrence rate of SAEs, MAAEs, AESIs;Occurrence rate of solicited local and systemic AE;Occurrence rate of unsolicited AE;Proportion of participants achieving a greater than or equal to 4-fold rise from baseline in IgG titer;Proportion of participants achieving a greater than or equal to 4-fold rise from baseline in wild-type neutralizing antibody titer

Cell-mediated response;GMFR of Anti-SAS-CoV-2 RBD IgG from baseline measured with ELISA;GMFR of Neutralizing anti-SARS-CoV-2 measured with live virus neutralization assay;GMT of Anti-SAS-CoV-2 RBD IgG measured with ELISA;GMT of Neutralizing anti-SARS-CoV-2 measured with live virus neutralization assay;Occurrence rate of Immediate Adverse Reaction (IAR);Occurrence rate of SAEs, MAAEs, AESIs;Occurrence rate of solicited local and systemic AE;Occurrence rate of unsolicited AE;Proportion of participants achieving a greater than or equal to 4-fold rise from baseline in IgG titer;Proportion of participants achieving a greater than or equal to 4-fold rise from baseline in wild-type neutralizing antibody titer